U.S. Anti-infective Agents Market Size & Outlook
U.S. anti-infective agents market, 2018-2030 (US$M)
Related Markets
U.S. anti-infective agents market highlights
- The U.S. anti-infective agents market generated a revenue of USD 45,935.3 million in 2024 and is expected to reach USD 46,470.5 million by 2030.
- The U.S. market is expected to grow at a CAGR of 0.7% from 2025 to 2030.
- In terms of segment, antivirals was the largest revenue generating type in 2024.
- Antifungals is the most lucrative type segment registering the fastest growth during the forecast period.
Anti-infective agents market data book summary
| Market revenue in 2024 | USD 45,935.3 million |
| Market revenue in 2030 | USD 46,470.5 million |
| Growth rate | 0.7% (CAGR from 2025 to 2030) |
| Largest segment | Antivirals |
| Fastest growing segment | Antifungals |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Antibacterials, Antivirals, Antifungals |
| Key market players worldwide | Pfizer Inc, Abbott Laboratories, Gilead Sciences Inc, Bristol-Myers Squibb Co, Merck & Co Inc, Sandoz Group AG ADR, B. Braun, Novo Holdings, Mankind Pharma, Bayer AG, AstraZeneca PLC, Boehringer Ingelheim Pharma |
Other key industry trends
- In terms of revenue, U.S. accounted for 33.9% of the global anti-infective agents market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. anti-infective agents market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 4,415.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Anti-infective Agents Market Scope
Anti-infective Agents Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. anti-infective agents market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-infective agents market will help companies and investors design strategic landscapes.
Antivirals was the largest segment with a revenue share of 54.02% in 2024. Horizon Databook has segmented the U.S. anti-infective agents market based on antibacterials, antivirals, antifungals covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. anti-infective agents market is experiencing significant growth due to rising demand for treatments against bacterial, viral, and fungal infections. Government support plays a critical role in this expansion, with agencies like the FDA expediting the approval process for innovative anti-infective agents, especially for treatments targeting multidrug-resistant pathogens.
Additionally, Zevtera is approved for treating community-acquired bacterial pneumonia in both adult and pediatric patients aged three months to under 18 years. Additionally, initiatives like the GAIN (Generating Antibiotic Incentives Now) Act provide incentives, such as extended market exclusivity, to encourage the development of novel antibiotics.
Reasons to subscribe to U.S. anti-infective agents market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. anti-infective agents market databook
-
Our clientele includes a mix of anti-infective agents market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. anti-infective agents market , including forecasts for subscribers. This country databook contains high-level insights into U.S. anti-infective agents market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. anti infective agents market size, by type, 2018-2030 (US$M)
U.S. Anti-infective Agents Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
